Atea reports $454.7M cash, plans global Phase 3 HCV program starting Q1 2025

Atea Pharmaceuticals, Inc.

Cash, cash equivalents and marketable securities $454.7M at Dec 31, 2024; cash runway into 2028.
Phase 2 study met primary endpoints: 98% SVR12 in per-protocol population, 95% in efficacy evaluable (n=256).
Global Phase 3 program for bemnifosbuvir + ruzasvir expected to initiate in Q1 2025; two open-label trials.
End-of-Phase 2 meeting with FDA scheduled January 2025 to discuss Phase 3 program design.
Company estimates global HCV market ~$3B annual net sales; regimen has potential best-in-class profile.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.